MaltoseCAS# 69-79-4 |
- Lactose
Catalog No.:BCN8387
CAS No.:14641-93-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 69-79-4 | SDF | Download SDF |
| PubChem ID | 294 | Appearance | Powder |
| Formula | C12H22O11 | M.Wt | 342.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol | ||
| SMILES | C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O | ||
| Standard InChIKey | GUBGYTABKSRVRQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Maltose Dilution Calculator
Maltose Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9214 mL | 14.6071 mL | 29.2141 mL | 58.4283 mL | 73.0353 mL |
| 5 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL | 11.6857 mL | 14.6071 mL |
| 10 mM | 0.2921 mL | 1.4607 mL | 2.9214 mL | 5.8428 mL | 7.3035 mL |
| 50 mM | 0.0584 mL | 0.2921 mL | 0.5843 mL | 1.1686 mL | 1.4607 mL |
| 100 mM | 0.0292 mL | 0.1461 mL | 0.2921 mL | 0.5843 mL | 0.7304 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cytarabine hydrochloride
Catalog No.:BCC4116
CAS No.:69-74-9
- Salicylic acid
Catalog No.:BCC4109
CAS No.:69-72-7
- D-Mannitol
Catalog No.:BCN2205
CAS No.:69-65-8
- Penicillin G Sodium
Catalog No.:BCC4638
CAS No.:69-57-8
- Ampicillin
Catalog No.:BCC1199
CAS No.:69-52-3
- Chlorpromazine HCl
Catalog No.:BCC4460
CAS No.:69-09-0
- Quinacrine 2HCl
Catalog No.:BCC4709
CAS No.:69-05-6
- Uncarine A
Catalog No.:BCN7767
CAS No.:6899-73-6
- Mulberrofuran A
Catalog No.:BCN3677
CAS No.:68978-04-1
- SKF 91488 dihydrochloride
Catalog No.:BCC6675
CAS No.:68941-21-9
- Kahweol
Catalog No.:BCC9006
CAS No.:6894-43-5
- H-D-Glu-OH
Catalog No.:BCC2936
CAS No.:6893-26-1
- 2,6-Dihydroxypurine
Catalog No.:BCN8476
CAS No.:69-89-6
- Hypaconitine
Catalog No.:BCN5988
CAS No.:6900-87-4
- Lycodoline
Catalog No.:BCN2506
CAS No.:6900-92-1
- Norchelerythrine
Catalog No.:BCN3643
CAS No.:6900-99-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
- Toltrazuril sulfone
Catalog No.:BCC2008
CAS No.:69004-04-2
- Tiotidine
Catalog No.:BCC5676
CAS No.:69014-14-8
- Genipin
Catalog No.:BCN5932
CAS No.:6902-77-8
- Germacrone
Catalog No.:BCN4981
CAS No.:6902-91-6
- ZM 306416
Catalog No.:BCC3964
CAS No.:690206-97-4
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
- Grifolin
Catalog No.:BCN7553
CAS No.:6903-07-7
Colloidal Silica Templated Mesoporous Carbons from a Maltose Solution for Use in Supercapacitor Electrodes.[Pubmed:29954549]
J Nanosci Nanotechnol. 2018 Oct 1;18(10):7142-7146.
A series of disordered mesoporous carbons (DMC) are synthesized via the colloidal silica template method by varying the mass ratio of silica to Maltose from 0.4 to 1.4. A gradual improvement in the surface area and porosity of the DMC is apparent with an increase in the ratio of silica to Maltose. The capacitance of the DMCs tends to increase linearly with their surface area. In particular, the DMC synthesized at a mass ratio of 1.4 exhibits the largest surface area of 1,152 m2/g and the highest capacitance of 175.4 F/g, comparable to the capacitance of other porous carbons with large surface areas (>2,000 m2/g). This feature may be attributed to its unique structural properties, such as the high pore interconnectivity allowing for easy access of the electrolyte ions. We believe that a higher capacitive performance can be achieved through further optimization studies (e.g., searching for better carbon precursors and adjusting the mass ratio of silica to carbon precursor).
Overexpression of SNF4 and deletions of REG1- and REG2-enhanced maltose metabolism and leavening ability of baker's yeast in lean dough.[Pubmed:29936578]
J Ind Microbiol Biotechnol. 2018 Sep;45(9):827-838.
Maltose metabolism of baker's yeast (Saccharomyces cerevisiae) in lean dough is suppressed by the glucose effect, which negatively affects dough fermentation. In this study, differences and interactions among SNF4 (encoding for the regulatory subunit of Snf1 kinase) overexpression and REG1 and REG2 (which encodes for the regulatory subunits of the type I protein phosphatase) deletions in Maltose metabolism of baker's yeast were investigated using various mutants. Results revealed that SNF4 overexpression and REG1 and REG2 deletions effectively alleviated glucose repression at different levels, thereby enhancing Maltose metabolism and leavening ability to varying degrees. SNF4 overexpression combined with REG1/REG2 deletions further enhanced the increases in glucose derepression and Maltose metabolism. The overexpressed SNF4 with deleted REG1 and REG2 mutant DeltaREG1DeltaREG2 + SNF4 displayed the highest Maltose metabolism and strongest leavening ability under the test conditions. Such baker's yeast strains had excellent potential applications.
